Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91


CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction.

Lee AJ, Roylance R, Sander J, Gorman P, Endesfelder D, Kschischo M, Jones NP, East P, Nicke B, Spassieva S, Obeid LM, Birkbak NJ, Szallasi Z, McKnight NC, Rowan AJ, Speirs V, Hanby AM, Downward J, Tooze SA, Swanton C.

J Pathol. 2012 Feb;226(3):482-94. doi: 10.1002/path.2998. Epub 2011 Oct 19.


Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.

Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E, Elustondo F, Chang J, Temple J, Ahmed AA, Brenton JD, Downward J, Nicke B.

Cancer Cell. 2007 Jun;11(6):498-512.


A CERTain role for ceramide in taxane-induced cell death.

Kolesnick R, Altieri D, Fuks Z.

Cancer Cell. 2007 Jun;11(6):473-5.


ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.

Washington MN, Suh G, Orozco AF, Sutton MN, Yang H, Wang Y, Mao W, Millward S, Ornelas A, Atkinson N, Liao W, Bast RC Jr, Lu Z.

Cell Death Dis. 2015 Aug 6;6:e1836. doi: 10.1038/cddis.2015.208.


Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells.

Akar U, Chaves-Reyez A, Barria M, Tari A, Sanguino A, Kondo Y, Kondo S, Arun B, Lopez-Berestein G, Ozpolat B.

Autophagy. 2008 Jul;4(5):669-79. Epub 2008 Apr 10.


Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents.

Sharma S, Zeng JY, Zhuang CM, Zhou YQ, Yao HP, Hu X, Zhang R, Wang MH.

Mol Cancer Ther. 2013 May;12(5):725-36. doi: 10.1158/1535-7163.MCT-12-1079. Epub 2013 Mar 6.


Chromosomal instability confers intrinsic multidrug resistance.

Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, Downward J, Szallasi Z, Tomlinson IP, Howell M, Kschischo M, Swanton C.

Cancer Res. 2011 Mar 1;71(5):1858-70. doi: 10.1158/0008-5472.CAN-10-3604.


LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy.

Nagelkerke A, Sieuwerts AM, Bussink J, Sweep FC, Look MP, Foekens JA, Martens JW, Span PN.

Endocr Relat Cancer. 2014 Jan 16;21(1):101-12. doi: 10.1530/ERC-13-0183. Print 2014 Feb.


Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.

Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Urruticoechea A, Martin-Castillo B, Menendez JA.

Oncotarget. 2012 Dec;3(12):1600-14.


Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.

Zhang C, Duan X, Xu L, Ye J, Zhao J, Liu Y.

Breast Cancer Res Treat. 2012 Dec;136(3):739-48. doi: 10.1007/s10549-012-2316-x. Epub 2012 Nov 2.


HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z.

Oncogene. 2003 May 22;22(21):3205-12.


MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.

Fessler SP, Wotkowicz MT, Mahanta SK, Bamdad C.

Breast Cancer Res Treat. 2009 Nov;118(1):113-24. doi: 10.1007/s10549-009-0412-3. Epub 2009 May 5.


Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors.

Yeh ES, Abt MA, Hill EG.

Breast Cancer Res Treat. 2015 Jan;149(1):91-8. doi: 10.1007/s10549-014-3227-9. Epub 2014 Dec 17.


P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration.

Yamagishi T, Sahni S, Sharp DM, Arvind A, Jansson PJ, Richardson DR.

J Biol Chem. 2013 Nov 1;288(44):31761-71. doi: 10.1074/jbc.M113.514091. Epub 2013 Sep 23.


Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells.

Ajabnoor GM, Crook T, Coley HM.

Cell Death Dis. 2012 Jan 26;3:e260. doi: 10.1038/cddis.2011.139.


Autophagy facilitates the development of resistance to the tumor necrosis factor superfamily member TRAIL in breast cancer.

Lv S, Wang X, Zhang N, Sun M, Qi W, Li Y, Yang Q.

Int J Oncol. 2015 Mar;46(3):1286-94. doi: 10.3892/ijo.2014.2812. Epub 2014 Dec 30.


Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial.

Jamal-Hanjani M, A'Hern R, Birkbak NJ, Gorman P, Grönroos E, Ngang S, Nicola P, Rahman L, Thanopoulou E, Kelly G, Ellis P, Barrett-Lee P, Johnston SR, Bliss J, Roylance R, Swanton C.

Ann Oncol. 2015 Jul;26(7):1340-6. doi: 10.1093/annonc/mdv178. Epub 2015 May 23.


Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells.

Lee J, Gollahon L.

Int J Oncol. 2013 Mar;42(3):839-47. doi: 10.3892/ijo.2013.1788. Epub 2013 Jan 22.


Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells.

Periyasamy-Thandavan S, Jackson WH, Samaddar JS, Erickson B, Barrett JR, Raney L, Gopal E, Ganapathy V, Hill WD, Bhalla KN, Schoenlein PV.

Autophagy. 2010 Jan;6(1):19-35.


Protein phosphatase 2Cepsilon is an endoplasmic reticulum integral membrane protein that dephosphorylates the ceramide transport protein CERT to enhance its association with organelle membranes.

Saito S, Matsui H, Kawano M, Kumagai K, Tomishige N, Hanada K, Echigo S, Tamura S, Kobayashi T.

J Biol Chem. 2008 Mar 7;283(10):6584-93. doi: 10.1074/jbc.M707691200. Epub 2007 Dec 28.

Supplemental Content

Support Center